Eli Lilly Reports Stellar Q1 Performance

Eli Lilly announced a remarkable 45% increase in revenue for the first quarter of fiscal 2025, reaching $12.73 billion. This growth was significantly driven by the strong sales performance of Mounjaro and Zepbound, highlighting the company's dominance in the weight-loss and diabetes medication markets.

Financial Highlights and Future Plans

The company also reported a net income of $2.76 billion, marking a 23% rise compared to the previous year. Despite facing $1.57 billion in acquired in-process R&D charges, earnings per share stood strong at $3.06.

CEO David Ricks shared insights on the success of the oral GLP-1 candidate, forgilzumab, and reiterated the company's revenue guidance for the year, projecting between $58 billion and $61 billion. In response to the soaring demand, Eli Lilly unveiled an ambitious $50 billion expansion plan for its US manufacturing capabilities.